Over the past year, global media has flooded us with news about novel forms of anti-obesity drugs demonstrating dramatic impact on weight reduction and diabetes control while also offering proof of protection against cardiovascular disease.
These drugs (mostly belonging to the class of glucagon-like peptide agonists) have now become blockbusters in high-income countries (HICs), earning billions for the manufacturers.
Patients are clamouring for them, and imitation products are emerging rapidly to exploit the demand-supply gaps.
Low and middle income countries (LMICs) have a different pattern of disordered nutrition. Many of them have several forms of malnutrition co-existing in their populations.


